INTRODUCTION {#s1}
============

Brain and central nervous system (CNS) malignancies refer to series of rarely occurred tumors \[[@R1]\]. According to the data of National Office for Cancer Prevention and Control in China, the estimated numbers of new cases and deaths in China were 101600 and 61000, respectively \[[@R2]\]. Gliomas, which are thought to arise from glial cells, make up about 80% of all malignant brain tumors \[[@R3]\]. Many risk factors have been identified as potential contributors to gliomas risk \[[@R4]\]. For example, ionizing radiation exposure, allergies or atopic disease(s) history, and potential influence of occupational exposures have been identified to be associated with gliomas risk \[[@R4]--[@R6]\]. Understanding of the genetic basis is a key component of preventive oncology. Genome-wide association studies (GWAS) have successfully identified a large number of common single-nucleotide polymorphisms (SNPs) influencing gliomas risk, while these SNPs only explain a small proportion of the genetic risk \[[@R7]\]. Furthermore, due to the common methodological challenges among gliomas studies include small sample sizes, heterogeneity of tumor subtypes, and retrospective exposure assessment, limited genetic loci were identified for gliomas risk \[[@R8]--[@R11]\].

SRY (Sex Determining Region Y)-Box (SOX) genes, which encode transcription factors belonging to the HMG (High Mobility Group) superfamily, have been identified to be associated with a large number of tumour types in vivo \[[@R12]--[@R14]\]. Among them, SOX9, which acts as a transcription factor that plays a central role in the development and differentiation of multiple cell lineages, were suggested to be associated with risk and prognosis of gliomas \[[@R15]--[@R17]\]. Rani et al \[[@R18]\] found MiR-145 functed as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Genetic association studies could provide solid evidence for the Oncogenic role of SOX9 gene in human malignant gliomas. To present, no studies have evaluated that whether genetic variants of SOX9 contribute to susceptibility of gliomas. Given the biological importance of SOX9 gene and its implication in gliomas, we performed the current two-stage, case--control study to investigated the association between tag SNPs in the SOX9 gene and gliomas susceptibility among Chinese population.

RESULTS {#s2}
=======

Demographic characteristics of the subjects {#s2_1}
-------------------------------------------

In current study, totally 400 gliomas patients and 400 healthy control were recruited in the discovery stage, while 800 gliomas patients and 800 healthy control were recruited in the validation stage. Table [1](#T1){ref-type="table"} shows the comparison of gliomas patients and controls by selective characteristics in both the discovery stage and the validation stage. No significant variation in age, gender, family history of cancer, and smoking status was found between gliomas patients and healthy controls in two stages (P \> 0.05), while the gliomas patients are more likely to be drinkers in the validation stage (P\<0.001).

###### Comparison of gliomas patients and controls by selective characteristics

  Variables                  Discovery stage   Validation stage                                       
  -------------------------- ----------------- ------------------ ------- ------------- ------------- --------------
  Age (years)                48.2±3.8          48.5±3.3           0.233   45.3±4.2      45.1±4.7      0.370
  Gender (male)              244 (61.0%)       248 (62.0%)        0.771   480 (60.0%)   468 (58.5%)   0.542
  Family history of cancer   86 (21.5%)        75 (18.8%)         0.332   160 (20.0%)   131 (16.4%)   0.060
  Smoking status                                                                                      
     Ever                    100 (25.0%)       97 (24.2%)         0.806   162 (20.2%)   132 (16.5%)   0.053
     Never                   300 (75.0%)       303 (75.8%)                638 (79.8%)   668 (83.5%)   
  Alcohol status                                                                                      
     Ever                    114 (28.5%)       104 (26.0%)        0.435   238 (29.8%)   160 (20.0%)   **P\<0.001**
     Never                   326 (81.5%)       336 (84.0%)                562 (70.2%)   640 (80.0%)   

Associations between SOX9 gene polymorphisms and gliomas risk in the discovery stage {#s2_2}
------------------------------------------------------------------------------------

Totally seven tagSNPs (rs1042667, rs918080, rs16977091, rs9893662, rs7502198, rs6501522, and rs9915657) are selected using the SNPinfo web-based software. As shown in Table [2](#T2){ref-type="table"}, the genotype frequencies of the selected SNPs and their associations with gliomas risk are presented. All of the genotype distributions for the seven tag SNPs were consistent with the HWE (P \> 0.05). Our results indicated that SOX9 rs1042667 was significant associated with increased gliomas risk (Allele C vs A: OR=1.26; 95% CI=1.04--1.54; P=0.019). Compared with the carriers of genotype AA, both those of genotype AC (OR=1.45; 95% CI=1.03--2.04) and CC (OR=1.55; 95% CI=1.06--2.28) had significantly increased gliomas risk. However, no significant trend was detected for rs918080, rs16977091, rs9893662, rs7502198, rs6501522, and rs9915657.

###### Association between SOX9 gene polymorphisms and the risk of gliomas in the discovery stage

  SNPs         Subject   Genotype (N)   OR (95 % CI)[^1^](#tfn_001){ref-type="table-fn"}   P value                                                               
  ------------ --------- -------------- -------------------------------------------------- --------- ------------------- ------------------- ------------------- -----------
  rs1042667    Case      91             195                                                114       1.26 (1.04--1.54)   1.45 (1.03--2.04)   1.55 (1.06--2.28)   **0.019**
               Control   122            180                                                98                                                                    
  rs918080     Case      271            100                                                29        1.20 (0.93-1.55)    0.99 (0.72-1.37)    1.87 (1.00-3.50)    0.156
               Control   280            104                                                16                                                                    
  rs16977091   Case      310            72                                                 18        0.92 (0.69-1.22)    0.75 (0.53-1.06)    1.43 (0.68-3.01)    0.564
               Control   296            92                                                 12                                                                    
  rs9893662    Case      193            140                                                67        1.20 (0.97-1.48)    0.91 (0.68-1.24)    1.65 (1.07-2.54)    0.087
               Control   200            158                                                42                                                                    
  rs7502198    Case      122            210                                                68        1.20 (0.88-1.64)    1.30 (0.85-1.98)    1.14 (0.94-1.39)    0.187
               Control   140            200                                                60                                                                    
  rs6501522    Case      250            116                                                34        1.07 (0.84-1.36)    0.92 (0.68-1.25)    1.41 (0.82-2.45)    0.549
               Control   250            126                                                24                                                                    
  rs9915657    Case      252            108                                                40        1.08 (0.85-1.36)    0.84 (0.61-1.14)    1.57 (0.93-2.66)    0.512
               Control   248            127                                                25                                                                    

adjusted for Age, gender, family history of cancer, smoking status and alcohol status

Validation analysis of the association between SOX9 rs1042667 and gliomas risk {#s2_3}
------------------------------------------------------------------------------

To validate the positive findings, the association between SOX9 rs1042667 and gliomas risk was evaluated in an independent stage (Table [3](#T3){ref-type="table"}). The genotype distribution for rs1042667 was also consistent with the HWE in the stage (P \> 0.05). The results showed that SOX9 rs1042667 was also significant associated with increased gliomas risk (Allele C vs A: OR=1.24; 95% CI=1.08-1.42; P=0.002). when merged two stages together, SOX9 rs1042667 was significant associated with increased gliomas risk (Allele C vs A: OR=1.25; 95% CI=1.11-1.40; P=1.2×10^−4^). Compared with the carriers of genotype AA, both those of genotype AC (OR=1.37; 95% CI=1.13-1.66) and CC (OR=1.53; 95% CI=1.22-1.91) had significantly increased gliomas risk. We also conducted stratified analysis by alcohol status. However, the results didn\'t changed materially (Table [4](#T4){ref-type="table"}).

###### Genotype frequencies of rs1042667 and association with risk of gliomas in validation stage and the merged results

  rs1042667              Cases (n=800)   Controls (n=800)   OR[^1^](#tfn_002){ref-type="table-fn"} (95% CIs)   *P* value
  ---------------------- --------------- ------------------ -------------------------------------------------- ----------------
  **validation stage**                                                                                         
     AA                  185 (23.1%)     236 (29.5%)        Reference                                          
     AC                  390 (48.8%)     374 (46.8%)        1.33 (1.05-1.69)                                   **0.019**
     CC                  225 (28.1%)     190 (23.7%)        1.51 (1.15-1.98)                                   **0.003**
   Additive model                                           1.24 (1.08-1.42)                                   **0.002**
  **Merged results**                                                                                           
     AA                  276 (23.0%)     358 (29.8%)        Reference                                          
     AC                  585 (48.7%)     554 (46.2%)        1.37 (1.13-1.66)                                   **1.6×10^−3^**
     CC                  339 (28.3%)     288 (24.0%)        1.53 (1.22-1.91)                                   **1.8×10^−4^**
   Additive model                                           1.25 (1.11-1.40)                                   **1.2×10^−4^**

adjusted for Age, gender, family history of cancer, smoking status and alcohol status

###### Association of rs1042667 with risk of gliomas stratified by Alcohol status

  rs1042667            Cases (n=1200)   Controls (n=1200)   OR[^1^](#tfn_003){ref-type="table-fn"} (95% CIs)   *P* value
  -------------------- ---------------- ------------------- -------------------------------------------------- ----------------
  **Ever drinkers**    352              264                                                                    
     AA                77 (21.9%)       80 (30.3%)          Reference                                          
     AC                173 (49.1%)      121 (45.8%)         1.48 (1.05-1.64)                                   **0.046**
     CC                102 (29.0%)      63 (23.9%)          1.68 (1.08-2.62)                                   **0.021**
   Additive model                                           1.31 (1.05-1.64)                                   **0.018**
  **Never drinkers**   848              936                                                                    
     AA                199 (23.5%)      278 (29.7%)         Reference                                          
     AC                412 (48.6%)      433 (46.3%)         1.33 (1.06-1.67)                                   **0.014**
     CC                237 (27.9%)      225 (24.0%)         1.47 (1.14-1.90)                                   **3.2×10^−3^**
   Additive model                                           1.23 (1.07-1.40)                                   **2.5×10^−3^**

adjusted for Age, gender, family history of cancer, and smoking status

DISCUSSION {#s3}
==========

In current study, we systematically evaluated whether genetic variants of SOX9 contribute to susceptibility of gliomas among Chinese population using a two-stage, case--control study. Results strongly indicated that SOX9 rs1042667 was significant associated with 1.25-flod increased gliomas risk, after adjusted by age, gender, family history of cancer, smoking status and alcohol status. To be best of our knowledge, this should be the first genetic association study which aims to evaluated the association between genetic variants of SOX9 and susceptibility of gliomas.

The prognosis for patients with gliomas is often very poor, only \~2% of which aged 65 years or older \[[@R19]\]. Previous studies revealed that genetic, behavioral, environmental and developmental contributed to gliomas risk, although only exposure to therapeutic or high-dose radiation was firmly established \[[@R20]\]. Studies of genetic syndromes, familial aggregation, linkage and mutagen sensitivity, which identified specific candidate genes including APC, hMLH1, hMSH2, PMS2, PTEN, NF1, NF2, et al, indicated the genetic susceptibility to gliomas \[[@R20]--[@R22]\]. Furthermore, genome-wide association studies (GWASs) show that common genetic variation contributes to the heritable risk of gliomas, and identify some new gliomas susceptibility loci, however, these only account for a small proportion of gliomas cases \[[@R8]\]. Additional studies, which aims to find more potential susceptibility loci to reveal the underlying genetic basis for gliomas, are needed and may yield increased insight into the development of this malignancy.

SOX9 gene is located on a gene desert on 17q24 in humans, and could recognize the CCTTGAG sequence along with other members of the HMG-box class DNA-binding proteins \[[@R23], [@R24]\]. Sox9 is required for the early differentiation of the prostate bud epithelia, and fully involved in the carcinogenesis, differentiation, and invasion prostate cancer through reactivating the WNT/beta-catenin signaling that mediates ductal morphogenesis \[[@R25]--[@R28]\]. Besides, Sox9 was also associated the carcinogenesis, development and prognosis of colorectal cancer, lung cancer, melanoma, hepatocellular carcinoma, skin tumors, and cervical cancer \[[@R29]--[@R37]\]. Pop et al \[[@R38]\] found a homozygous nonsense mutation in SOX9 in the dominant disorder campomelic dysplasia. Zhang et al \[[@R39]\] identified that multiple genetic variants mapping to a unique enhancer looping to the SOX9 oncogene could account for the risk associated with 17q24.3 locus of prostate cancer.

In current study, we confirmed that SOX9 rs1042667 was significantly associated with increased gliomas risk (Allele C vs A: OR=1.25; 95% CI=1.11-1.40; P=1.2×10^−4^). Using Quanto software (<http://biostats.usc.edu/Quanto.html>), we found we have 97% statistical power to get such an association. Rs1042667 located at the 3′ UTR region of the SOX9 gene. Using RegulomeDB \[[@R40], [@R41]\], rs1042667 was identified to be likely to affect binding capacity with other genes and transcription factors. While it was reported to be associated with the expression of AC005152.2 in Heart Left Ventricle, and could alter regulatory motifs, including GR_disc4, TATA_disc1, THAP1_disc2, and YY1_disc1, when analyzed by HaploReg v4.1 \[[@R42]\]. It was also predicted to be the binding site of transcription factors (ATF6_01, CACD_01, CDPCR3_01, et al) using the SNPinfo package (<https://snpinfo.niehs.nih.gov/cgi-bin/snpinfo/snpfunc.cgi>). Overall, our findings provided evidence for the important role of SOX9 gene in the tumorigenesis of gliomas.

Several limitations should be considered when interpreting the results of this study. First, due to the natural of case-control study design, selection and information bias might be unavoidable. We have tried our best to eliminate this by matching the control by age, gender, and race from the same hospital, a face to face interview, and unified training of the investigators. Second, gene-environment interactions was not detected in current study, which may be caused by the relatively not very large sample size.

Conclusively, the present two-stage, case-control study revealed that SOX9 rs1042667 was associated with increased gliomas risk in a Chinese population. Further functional and genetic association studies in larger population, with different ethnic groups included, are warranted to further validate our results and explore the possible mechanism of SOX9 gene in the carcinogenesis and development of gliomas.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

All of the gliomas cases received treatments from the Tangdu Hospital until November 2015, we recruited 1,200 genetically unrelated Chinese patients with newly diagnosed and histopathologically confirmed primary gliomas. We also included a total of 1,200 age-, gender-, race-matched, cancer-free volunteers recruited from the same hospital. The response rate was approximately 95% and 92% for gliomas subjects and cancer-free controls, respectively. All the participants have no previous history of cancer and CNS-related diseases. Structured-interviewer-administered questionnaires were used to collect data on demographic characteristics and potential gliomas risk factors. The study was approved by the Institutional Review Board of Tangdu Hospital. All of the participants provided written informed consent by themselves or their guardians.

SNP selection and genotyping {#s4_2}
----------------------------

The tag SNPs of SOX9 gene and its 10kb flanking region were selected using SNPinfo (<http://snpinfo.niehs.nih.gov/>) based on the criteria of minor allele frequency(MAF) \>5% for Chinese Han subjects; Seven tag SNPs in the SOX9 gene that met the criteria were chosen in this study (Figure [1](#F1){ref-type="fig"}). Genomic DNAs were extracted by Qiagen DNA blood kit (Qiagen, Hilden, Germany) from whole blood samples collected from all subjects. The extraction of genomic DNAs was performed following the manufacturer\'s protocols. SNP genotyping was performed by Sequenom MassArray iPLEX platform (Sequenom Inc., San Diego, CA, USA). To validate the accuracy of genotyping results and for quality control, approximately 10% of the samples were randomly selected and genotyped with sequencing. Results showed that the concordance for the quality control samples was 100%.

![tag SNP selection of the SOX9 gene](oncotarget-07-65916-g001){#F1}

Statistical analysis {#s4_3}
--------------------

All the data was analyzed with SPSS software version 13.0 (SPSS Inc, Chicago, IL, USA). All statistical tests were two-sided, with a significance level of P \< 0.05. The chi-square test was used to compare the difference in gender, family history of cancer, smoking status and alcohol status between gliomas patients and healthy controls, while Student\'s paired t test was performed to compare the difference in age between gliomas patients and healthy controls. Genotypic frequencies in controls for each SNP were tested for departure from HWE using goodness-of-fit χ2 test. Odds ratios and corresponding 95% confidence intervals (CIs) were used to estimate the association between selected polymorphisms and gliomas risk. Adjusted ORs were calculated by multivariate analysis with unconditional logistic regression, with adjustment for age, gender, family history of cancer, smoking status and alcohol status.
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